.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,028,186

« Back to Dashboard

Details for Patent: 6,028,186

Title: High affinity nucleic acid ligands of cytokines
Abstract:Methods are described for the identification and preparation of high-affinity nucleic acid ligands to cytokines. Included in the invention are specific nucleic acid ligands to IFN-gamma, IL-4, IL-10, TNF-alpha, and RANTES.
Inventor(s): Tasset; Diane (Boulder, CO), Pagratis; Nikos (Boulder, CO), Jayasena; Sumedha (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Jun 07, 1995
Application Number:08/481,710
Claims:1. A purified and isolated non-naturally occurring nucleic acid ligand to a cytokine selected from the group consisting of interleukin-4 (IL4), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-alpha) and Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES) protein.

2. The purified and isolated non-naturally occurring nucleic acid ligand of claim 1 wherein said nucleic acid ligand is single-stranded.

3. The purified and isolated non-naturally occurring nucleic acid ligand of claim 2 wherein said nucleic acid ligand is RNA.

4. The purified and isolated non-naturally occurring nucleic acid ligand of claim 2 wherein said nucleic acid ligand is DNA.

5. A nucleic acid ligand to a cytokine selected from the group consisting of IL-4, IL-10, TNF-.alpha. and RANTES, identified according to the method comprising:

a) preparing a candidate mixture of nucleic acids;

b) contacting the candidate mixture of nucleic acids with said cytokine, wherein nucleic acids having an increased affinity to said cytokine relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to said cytokine, whereby a nucleic acid ligand of said cytokine may be identified.

6. The purified and isolated non-naturally occuring RNA ligand to IFN-gamma of claim 5 wherein said ligand is selected from the group consisting of the sequences set forth in Tables 3 and 4 (SEQ ID NOS: 7-73).

7. The purified and isolated non-naturally occurring RNA ligand of claim 3 wherein said ligand is to IL-4.

8. The purified and isolated non-naturally occurring RNA ligand to IL-4 of claim 7 wherein said ligand is selected from the group consisting of the sequences set forth in Tables 7 and 8 (SEQ ID NOS: 79-185).

9. The purified and isolated non-naturally occurring RNA ligand to IL-4 of claim 7 wherein said ligand is substantially homologous to and has substantially the same ability to bind IL-4 as a ligand selected from the group consisting of the sequences set forth in Tables 7 and 8 (SEQ ID NOS: 79-185).

10. The purified and isolated non-naturally occurring RNA ligand to IL-4 of claim 7 wherein said ligand has substantially the same structure and substantially the same ability to bind IL-4 as a ligand selected from the group consisting of the sequences set forth in Tables 7 and 8 (SEQ ID NOS:79-185).

11. The purified and isolated non-naturally occurring RNA ligand of claim 3 wherein said ligand is to IL-10.

12. The purified and isolated non-naturally occurring RNA ligand to IL-10 of claim 11 wherein said ligand is selected from the group consisting of the sequences set forth in Table 10 (SEQ ID NOS: 189-205).

13. The purified and isolated non-naturally occurring RNA ligand to IL-10 of claim 11 wherein said ligand is substantially homologous to and has substantially the same ability to bind IL-10 as a ligand selected from the group consisting of the sequences set forth in Table 10 (SEQ ID NOS: 189-205).

14. The purified and isolated non-naturally occurring RNA ligand to IL-10 of claim 11 wherein said ligand has substantially the same structure and substantially the same ability to bind IL-10 as a ligand selected from the group consisting of the sequences set forth in Table 10 (SEQ ID NOS: 189-205).

15. The purified and isolated non-naturally occuring RNA ligand of claim 3 wherein said ligand id to TNF-alpha.

16. The purified and isolated non-naturally occurring RNA ligand to TNF-alpha of claim 15 wherein said ligand is selected from the group consisting of the sequences set forth in Table 12 (SEQ ID NOS: 209-255).

17. The purified and isolated non-naturally occurring RNA ligand to TNF-alpha of claim 15 wherein said ligand is substantially homologous to and has substantially the same ability to bind TNF-alpha as a ligand selected from the group consisting of the sequences set forth in Table 12 (SEQ ID NOS:209-255).

18. The purified and isolated non-naturally occurring RNA ligand to TNF-alpha of claim 15 wherein said ligand has substantially the same structure and substantially the same ability to bind TNF-alpha as a ligand selected from the group consisting of the sequences set forth in Table 12 (SEQ ID NOS: 189-205).

19. The purified and isolated non-naturally occurring nucleic acid ligand of claim 1 wherein said ligand is to RANTES.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc